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Abstract
Several biomarkers have been preferred for the early diagnosis of pancreatic adenocan-
cer (PAC), but most are not ready to be included as part of the routine diagnostic algo-
rithm because they still lack sensitivity, specificity or reproducibility. CA19-9 is the most 
widely used serum-based marker for the diagnosis and follow-up of pancreatic cancer. 
However, CA19-9 lacks sensitivity for early or small-diameter pancreatic cancers. For 
more than 3 decades, information on neutrophil/lymphocyte ratio (NLR), platelet/lym-
phocyte ratio (PLR), mean platelet volume (MPV) has been widely available to health 
care practitioners, as part of the data provided in the full blood count. However, these 
biomarkers have more than used in the routine. The present chapter shares the prog-
nostic significance of the hematological parameters in the light of our own findings and 
recent studies in the literature.
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1. Introduction
Pancreatic adenocarcinoma is a devastating disease with an extremely poor prognosis and 
prompt diagnostic evaluation is vital when PAC is suspected. CA19-9 is the most widely 
used serum-based marker for the diagnosis and follow-up of pancreatic cancer [1]. The 
diagnostic role of CA19-9 as a test for the detection of pancreatic malignancy remains 
poorly defined, because, as in other diagnostic modalities, the utility of CA19-9 has several 
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confounding limitations. The sensitivity and specificity of CA19-9 vary, ranging from 70 
to 90% and 68 to 91%, respectively. However, CA19-9 lacks sensitivity for early or small-
diameter pancreatic cancers. Poorly differentiated pancreatic cancers also appear to pro-
duce less CA19-9 than either moderately or well-differentiated cancers. Another limitation 
is that CA19-9 can also be elevated in benign inflammatory and cholestatic diseases of the 
pancreaticobiliary tract [2, 3].
After inflammatory processes have emerged as key mediators of pancreatic cancer develop-
ment and progression, many inflammatory pathways have been identified in recent years. 
Neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and mean platelet 
volume (MPV) are the most used in the literature [4–6]. Elevated NLR has reportedly been 
associated with poor survival following resection or chemotherapy in a variety of cancer. 
In colorectal cancer, an increasing number of studies have reported an association between 
elevated NLR and poor prognosis [7]. The first study done by us, including a total of 41 resect-
able PAC patients and 43 age-matched and sex-matched healthy participants [8]. NLR, PLR, 
and MPV were significantly higher in preoperative stage 1 and stage 2 PAC patients com-
pared with age-matched and sex matched healthy participants (5.51 vs. 2.5, P = 0.002; 180 
vs. 134, P = 0.017; 9.2 vs. 2.5 fl, P = 0.004) (Table 1). Our results suggested that NLR, PLR and 
MPV might be used as easily available additional biomarkers for PAC in screening general 
population (Figure 1).
The role of new tumor marker PLR has been defined recently in the prognosis of PAC [9]. 
Miglani et al. reported that PLR has been at least as good as CA 19-9 as diagnostic marker 
to differentiate between malignant and inflammatory head mass of pancreas. This is based 
on the fact that PAC causes thrombosis and lymphocytopenia. Platelet activation is a link in 
the pathophysiology of diseases prone to thrombosis and inflammation. Lymphocytopenia 
occurs due to systemic inflammation caused by cancers that release a number of inhibitory 
immunologic mediators [10]. The diagnostic value of platelet size has recently been shown 
to be elevated in neoplastic disorders particularly in gastric cancer. Moreover, it has been 
determined that platelet size has a predictive value for bone marrow metastasis in patients 
with solid tumors [11]. Numerous platelet markers, including MPV, have been investigated 
in connection with both thrombosis and inflammation.
PAC Control P value
Neutrophil 6092 ± 4212 3944 ± 1219 0.002
PLT 230 ± 84 244 ± 64 0.39
MPV 9.21 ± 1.2 8.5 ± 0.82 0.004
NLR 5.51 ± 7.3 2.5 ± 1.1 0.002
PLR 180 ± 103 135 ± 65 0.017
Abbreviations: PLT: platelet; MPV: mean platelet volume; NLR: neutrophil/lymphocyte ratio; PLR: platelet/lymphocyte 
ratio; PAC: pancreatic cancer
Table 1. Hematological results of the patients and controls.
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2. Inflammation and PAC
In the development and progression of cancer, inflammation is a crucial and essential process 
[12]. Persistence of the inflammatory process within the tumor leads to an increase in the pro-
liferation of tumor cells, angiogenesis, and the inhibition of apoptosis [13, 14]. Several reports 
have suggested that markers of systemic inflammation including cytokines, C-reactive pro-
tein, NLR, and PLR may provide useful information on the prognosis of colorectal gastro-
intestinal cancer [15, 16]. Thus, pathogenesis of PAC appears to be an inflammation-driven 
malignancy, as well as colorectal gastrointestinal cancer. Usually, cancer cells are a source of 
inflammatory cytokines and growth factors. Interleukin-6 (IL-6) is an inflammatory cytokine 
that can cause carcinogenesis through several signal pathways involved in carcinogenesis, as 
well as metastasis of a variety of malignancies, including PAC [17].
It has been shown that PAC patients have higher levels of IL-6 compared with a healthy 
control group [18]. We acknowledged that IL-6 is released from leukocytes and is also able to 
activate the production of IL-6 by tumor cells through the IL-6 receptor. Besides their role in 
homeostasis, platelets and leucocytes take part in the pathophysiology of tumor angiogenesis 
[19]. Platelets are known to be the major transporter of vascular endothelial growth factor, 
which is the target for antiangiogenic therapies. Vascular endothelial growth factor accel-
erates the formation of blood vessels in the tumor and facilitates infiltration and spread to 
Figure 1. Receiver operating characteristic curves NLR, PLR and MPV for predicting stage 1 and stage 2 pancreatic 
cancer. Abbreviations: MPV: mean platelet volume; NLR: neutrophil/lymphocyte ratio; PLR: platelet/lymphocyte ratio.
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adjacent tissues, which in turn promotes the formation of metastases [20]. Solid tumors such 
as renal, gastric, and colon malignancies produce IL-6, which induces the proliferation and 
differentiation of megakaryocyte progenitors through specific receptors. This process causes 
platelet activation and aggregation. Platelet size has been shown to reflect changes in the level 
of platelet stimulation and the rate of platelet production.
According to the literature, lymphocytes play a key role in cytotoxic cell death and the pro-
duction of cytokines that inhibit proliferation and metastatic spread of tumor cells. In contrast, 
neutrophils have a protumor effect by being the primary source of circulating angiogenesis-
regulating chemokines, growth factors, and proteases [4]. Elevated neutrophil levels may result 
in an increase in angiogenesis, which promotes development and progression of the neoplasm 
[6]. Therefore, NLR can be considered as the balance between protumor inflammatory status 
and antitumor immune status. At present, there is little information on the relevance of these 
prognostic markers to both diagnosis and monitoring of PAC. Similarly as being in our expe-
rience, newly diagnosed PAC patients have high NLR and PLR values than healthy human.
3. Diagnostic weakness and missing points
Even with decades passed, measurement of this parameter is still not standardized, as it can 
easily be obtained with electronic meters. This is a major flaw because many pre-analytical 
and analytical variables can affect platelet size. The pre-analytical variables include vascular 
occlusion method, the correctness of the filling of the vial and the mixing of the sample, the 
type of anticoagulant, the storage temperature and the duration of the analysis. Any inflam-
matory or malignant process can lead to an increase in these parameters [21].
In practice, these markers, if used alone, may have a low positive predictive value in screening 
an asymptomatic population. Getting in touch with EDTA, ethylene diamine tetra acetic acid, the 
most common anticoagulant used in laboratory practice, effects the platelet morphology and 
leads to swelling and an increase in volumes. The differences in the methodology of platelet 
counting with different automated analytics are most like to be major analytical variable for 
the measurement [22].
The poor standardization of the number of physiological variables affecting platelet size and the 
poor standardization of this parameter makes it very unlikely that small differences in this param-
eter, defined by clinical trials in various clinical conditions, could be used for clinical purposes. In 
the future, better methodological standardization and more personalized reference intervals may 
make them as a reliable parameter for differential diagnosis and prognostic identification in daily 
clinical practice, but there is a need for well-designed clinical trials to confirm this hypothesis [23].
4. Diagnostic efficiency and strengths
Certainly, the most important advantage is their cost-efficiency. In routine analyzes of PAC, 
several parameters have been being used at high cost. These parameters have so low cost 
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which cannot be easily overlooked. Additionally, we speculate that increased MPV in a patient 
group newly diagnosed with PAC may be a reflection of ongoing inflammation, and it can be 
related to increased levels of cytokines, particularly IL-6. Thus, we suggest that MPV could 
be used for detection of PAC instead of CA19-9. Increased MPV value, an indicator of platelet 
volume, points the presence of a subpopulation of young, metabolically and enzymatically 
more active platelets taking part in the process of homeostasis. NLR and PLR are two repre-
sentative indices of systemic inflammation [24]. It has been shown that a preoperative NLR 
of greater than 4 or 5 is associated with a poor outcome in gastric cancer, non-small-cell lung 
cancer, and ovarian cancer. Neutrophils and leukocytes play a crucial role in the host systemic 
inflammatory response. A nonspecific systemic inflammatory response due to a tumor leads 
to an increase in the levels of circulating neutrophils and an elevated NLR, all of which are 
also clearly demonstrated in our study.
5. Conclusion
As in our results and the literature, the patients with PAC have higher levels of these bio-
markers than healthy people. Thus, patients with high NLR, PLR, and MPV with suspicious 
symptoms and/or signs of PAC are candidates for early evaluation, which can prevent delay 
in the diagnosis of PAC. Therefore, prospective studies with inflammatory marker screening 
as IL-6, TNF on a larger number of asymptomatic patients are needed to compare the perfor-
mance of NLR, PLR, and MPV with that of other diagnostic and monitoring tests to confirm 
their diagnostic utility.
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